Milton C. Ault III - Jul 20, 2021 Form 4 Insider Report for Alzamend Neuro, Inc. (ALZN)

Role
10%+ Owner
Signature
/s/ Milton C. Ault, III
Stock symbol
ALZN
Transactions as of
Jul 20, 2021
Transactions value $
$15,123
Form type
4
Date filed
7/22/2021, 09:30 PM
Previous filing
Jul 19, 2021
Next filing
Jul 21, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALZN Common Stock Purchase $15.6K +3K +0.06% $5.20* 5.33M Jul 20, 2021 By Digital Power Lending, LLC F1, F2
transaction ALZN Common Stock Purchase -$2.73K -500 -0.01% $5.45* 5.33M Jul 21, 2021 By Digital Power Lending, LLC F2, F3
holding ALZN Common Stock 15M Jul 20, 2021 By Ault Life Sciences, Inc. F4
holding ALZN Common Stock 10M Jul 20, 2021 By Ault Life Sciences Fund, LLC F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALZN Call Option (right to buy) Purchase $2.25K +12 $187.18 12 Jul 22, 2021 Common Stock 1.2K $7.50 By Digital Power Lending, LLC F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $5.2015. The range of purchase prices on the transaction date was $5.08 to $5.30 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
F2 Digital Power Lending, LLC ("DPL") is a wholly-owned subsidiary of Ault Global Holdings, Inc. ("AGH"). Mr. Ault, the Executive Chairman of AGH, is deemed to have voting and investment power with respect to the securities held of record by DPL.
F3 The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $5.4544. The range of purchase prices on the transaction date was $5.44 to $5.46 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
F4 Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences, Inc.
F5 Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences Fund, LLC.
F6 The security listed is an exchange-traded option contract. Exchange-traded options are immediately exercisable and remain exercisable until expiration.
F7 The options were purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $187.18. The range of purchase prices on the transaction date was $160.51 to $192.51. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of options purchased at each price.